Jennifer J. Trowbridge

Jennifer J. Trowbridge

Auto-generated profile, based on publicly available information

Jennifer J. Trowbridge

The Jackson Laboratory, Bar Harbor, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Cell Stem Cell
Verified
Journal Article
Closed access
KYKira Young
Kira Young
EEElizabeth Eudy
Elizabeth Eudy
RBRebecca Bell
Rebecca Bell
MLMatthew A. Loberg
Matthew A. Loberg
TSTim Stearns
Tim Stearns
JTJennifer J. Trowbridge
Jennifer J. Trowbridge

15 June 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JTJennifer J. Trowbridge
Jennifer J. Trowbridge
DSDaniel T. Starczynowski
Daniel T. Starczynowski
With a growing aged population, there is an imminent need to develop new therapeutic strategies to ameliorate disorders of hematopoietic aging, including clonal hematopoiesis and myelodysplastic syndrome (MDS). Cell-intrinsic dysregulation of innate immune- and inflammatory-related pathways as well as systemic inflammation have been implicated in hematopoietic defects associated with aging, clonal hematopoiesis, and MDS. Here, we review and discuss the role of dysregulated innate immune and inflammatory signaling that contribute to the competitive advantage and clonal dominance of preleukemic and MDS-derived hematopoietic cells. We also propose how emerging concepts will further reveal critical biology and novel therapeutic opportunities.

28 January 2019 in Leukemia
Verified
Journal Article
Open access
PDF file
MLMatthew A. Loberg
Matthew A. Loberg
RBRebecca K. Bell
Rebecca K. Bell
LGLeslie O. Goodwin
Leslie O. Goodwin
EEElizabeth Eudy
Elizabeth Eudy
LMLinde Miles
Linde Miles
JTJennifer J. Trowbridge
Jennifer J. Trowbridge
Clonal hematopoiesis (CH) is a common aging-associated condition with increased risk of hematologic malignancy. Knowledge of the mechanisms driving evolution from CH to overt malignancy has been hampered by a lack of in vivo models that orthogonally activate mutant alleles. Here, we develop independently regulatable mutations in DNA methyltransferase 3A (Dnmt3a) and nucleophosmin 1 (Npm1), observed in human CH and AML, respectively. We find Dnmt3a mutation expands hematopoietic stem and multipotent progenitor cells (HSC/MPPs), modeling CH. Induction of mutant Npm1 after development of Dnmt3a-mutant CH causes progression to myeloproliferative disorder (MPD), and more aggressive MPD is observed with longer latency between mutations. MPDs uniformly progress to acute myeloid leukemia (AML) following transplant, accompanied by a decrease in HSC/MPPs and an increase in myeloid-restricted progenitors, the latter of which propagate AML in tertiary recipient mice. At a molecular level, progression of CH to MPD is accompanied by selection for mutations activating Ras/Raf/MAPK signaling. Progression to AML is characterized by additional oncogenic signaling mutations (Ptpn11, Pik3r1, Flt3) and/or mutations in epigenetic regulators (Hdac1, Idh1, Arid1a). Together, our study demonstrates that Npm1 mutation drives evolution of Dnmt3a-mutant CH to AML and rate of disease progression is accelerated with longer latency of CH.

10 October 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KYKira Young
Kira Young
SBSneha Borikar
Sneha Borikar
RBRebecca Bell
Rebecca Bell
LKLauren Kuffler
Lauren Kuffler
VPVivek Philip
Vivek Philip
JTJennifer J. Trowbridge
Jennifer J. Trowbridge
Declining immune function with age is associated with reduced lymphoid output of hematopoietic stem cells (HSCs). Currently, there is poor understanding of changes with age in the heterogeneous multipotent progenitor (MPP) cell compartment, which is long lived and responsible for dynamically regulating output of mature hematopoietic cells. In this study, we observe an early and progressive loss of lymphoid-primed MPP cells (LMPP/MPP4) with aging, concomitant with expansion of HSCs. Transcriptome and in vitro functional analyses at the single-cell level reveal a concurrent increase in cycling of aging LMPP/MPP4 with loss of lymphoid priming and differentiation potential. Impaired lymphoid differentiation potential of aged LMPP/MPP4 is not rescued by transplantation into a young bone marrow microenvironment, demonstrating cell-autonomous changes in the MPP compartment with aging. These results pinpoint an age and cellular compartment to focus further interrogation of the drivers of lymphoid cell loss with aging.

28 September 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JSJennifer M. SanMiguel
Jennifer M. SanMiguel
EEElizabeth Eudy
Elizabeth Eudy
MLMatthew A. Loberg
Matthew A. Loberg
KYKira A. Young
Kira A. Young
JMJayna J. Mistry
Jayna J. Mistry
JTJennifer J. Trowbridge
Jennifer J. Trowbridge
Clonal hematopoiesis resulting from the enhanced fitness of mutant hematopoietic stem cells (HSC) associates with both favorable and unfavorable health outcomes related to the types of mature mutant blood cells produced, but how this lineage output is regulated is unclear. Using a mouse model of a clonal hematopoiesis–associated mutation, DNMT3AR882/+ (Dnmt3aR878H/+), we found that aging-induced TNFα signaling promoted the selective advantage of mutant HSCs and stimulated the production of mutant B lymphoid cells. The genetic loss of the TNFα receptor TNFR1 ablated the selective advantage of mutant HSCs without altering their lineage output, whereas the loss of TNFR2 resulted in the overproduction of mutant myeloid cells without altering HSC fitness. These results nominate TNFR1 as a target to reduce clonal hematopoiesis and the risk of associated diseases and support a model in which clone size and mature blood lineage production can be independently controlled to modulate favorable and unfavorable clonal hematopoiesis outcomes. Significance: Through the identification and dissection of TNFα signaling as a key driver of murine Dnmt3a-mutant hematopoiesis, we report the discovery that clone size and production of specific mature blood cell types can be independently regulated. See related commentary by Niño and Pietras, p. 2724. This article is highlighted in the In This Issue feature, p. 2711

10 August 2023 in Blood
Verified
Journal Article
Open access
PDF file
PDPatricia A. Colom Díaz
Patricia A. Colom Díaz
JMJayna J. Mistry
Jayna J. Mistry
JTJennifer J. Trowbridge
Jennifer J. Trowbridge
With aging, hematopoietic stem cells (HSCs) have an impaired ability to regenerate, differentiate, and produce an entire repertoire of mature blood and immune cells. Owing to dysfunctional hematopoiesis, the incidence of hematologic malignancies increases among elderly individuals. Here, we provide an update on HSC-intrinsic and -extrinsic factors and processes that were recently discovered to contribute to the functional decline of HSCs during aging. In addition, we discuss the targets and timing of intervention approaches to maintain HSC function during aging and the extent to which these same targets may prevent or delay transformation to hematologic malignancies.